1.
Di Angelantonio E, Kaptoge S, Wormser D, Willeit P, Butterworth AS, Bansal N, O'Keeffe
LM, Gao P, Wood AM, Burgess S et al: Association of Cardiometabolic Multimorbidity With Mortality. JAMA 2015, 314(1):52-60.
2.
Huxley R, Barzi F, Woodward M: Excess risk of fatal coronary heart disease associated with diabetes in men and women:
meta-analysis of 37 prospective cohort studies. BMJ 2006, 332(7533):73-78.
3.
Lloyd-Jones DM, Leip EP, Larson MG, D'Agostino RB, Beiser A, Wilson PW, Wolf PA, Levy
D: Prediction of lifetime risk for cardiovascular disease by risk factor burden at 50
years of age. Circulation 2006, 113(6):791-798.
4.
Reusch JE DB: Atherosclerosis in diabetes and insulin resistance. Diabetes Obes Metab 2007(9):455-463.
5.
American Diabetes Association: Standards of medical care in diabetes—2017 abridged for primary care providers. Clinical Diabetes 2017, 35(1):5-26.
6.
SEMDSA Type 2 Diabetes Guidelines Expert Committee: SEMDSA 2017 guidelines for the management of type 2 diabetes mellitus. J Endocr Metab Diabetes S Afr 2017, 22(1 Suppl 1):S1 - S196.
7.
Colhoun HM, Betteridge DJ, Durrington PN, Hitman GA, Neil HA, Livingstone SJ, Thomason
MJ, Mackness MI, Charlton-Menys V, Fuller JH: Primary prevention of cardiovascular disease with atorvastatin in type 2 diabetes
in the Collaborative Atorvastatin Diabetes Study (CARDS): a multicentre randomised
placebo-controlled trial. Lancet 2004, 364(9435):685-696.
8.
Collins R, Armitage J, Parish S, Sleigh P, Peto R: MRC/BHF Heart Protection Study of cholesterol-lowering with simvastatin in 5963 people
with diabetes: a randomised placebo-controlled trial. Lancet 2003, 361(9374):2005-2016.
9.
Sever PS, Poulter NR, Dahlof B, Wedel H, Collins R, Beevers G, Caulfield M, Kjeldsen
SE, Kristinsson A, McInnes GT et al: Reduction in cardiovascular events with atorvastatin in 2,532 patients with type 2
diabetes: Anglo-Scandinavian Cardiac Outcomes Trial--lipid-lowering arm (ASCOT-LLA). Diabetes Care 2005, 28(5):1151-1157.
10.
Baigent C, Blackwell L, Emberson J, Holland LE, Reith C, Bhala N, Peto R, Barnes EH,
Keech A, Simes J et al: Efficacy and safety of more intensive lowering of LDL cholesterol: a meta-analysis
of data from 170,000 participants in 26 randomised trials. Lancet 2010, 376(9753):1670-1681.
11.
de Vries FM, Denig P, Pouwels KB, Postma MJ, Hak E: Primary prevention of major cardiovascular and cerebrovascular events with statins
in diabetic patients: a meta-analysis. Drugs 2012, 72(18):2365-2373.
12.
Hayward RA, Hofer TP, Vijan S: Narrative review: lack of evidence for recommended low-density lipoprotein treatment
targets: a solvable problem. Annals of internal medicine 2006, 145(7):520-530.
13.
Perk J, De Backer G, Gohlke H, Graham I, Reiner Z, Verschuren M, Albus C, Benlian
P, Boysen G, Cifkova R et al: European Guidelines on cardiovascular disease prevention in clinical practice (version
2012). The Fifth Joint Task Force of the European Society of Cardiology and Other
Societies on Cardiovascular Disease Prevention in Clinical Practice (constituted by
representatives of nine societies and by invited experts). European heart journal 2012, 33(13):1635-1701.
14.
Perreault S, Dragomir A, Blais L, Berard A, Lalonde L, White M, Pilon D: Impact of better adherence to statin agents in the primary prevention of coronary
artery disease. European journal of clinical pharmacology 2009, 65(10):1013-1024.
15.
Kearney P, Blackwell L, Collins Ra, Keech A, Simes J, Peto R, Armitage J, Baigent
C: Cholesterol Treatment Trialists’(CTT) Collaborators. Efficacy of cholesterol-lowering
therapy in 18,686 people with diabetes in 14 randomised trials of statins: a meta-analysis. Lancet 2008, 371(9607):117-125.
16.
Eliasson B, Svensson AM, Miftaraj M, Jonasson JM, Eeg-Olofsson K, Sundell KA, Gudbjornsdottir
S: Clinical use and effectiveness of lipid lowering therapies in diabetes mellitus--an
observational study from the Swedish National Diabetes Register. PLoS One 2011, 6(4):e18744.
17.
Balder JW, Scholtens S, de Vries JK, van Schie LM, Boekholdt SM, Hovingh GK, Kamphuisen
PW, Kuivenhoven JA: Adherence to guidelines to prevent cardiovascular diseases: The LifeLines cohort study. The Netherlands journal of medicine 2015, 73(7):316-323.
18.
Berthold HK, Gouni-Berthold I, Bohm M, Krone W, Bestehorn KP: Patterns and predictors of statin prescription in patients with type 2 diabetes. Cardiovascular diabetology 2009, 8:25.
19.
Harrison TN, Scott RD, Cheetham TC, Chang S-C, Hsu J-WY, Wei R, Ling Grant DS, Boklage
SH, Romo-LeTourneau V, Reynolds K: Trends in Statin Use 2009-2015 in a Large Integrated Health System: Pre- and Post-2013
ACC/AHA Guideline on Treatment of Blood Cholesterol. Cardiovascular drugs and therapy 2018, 32(4):397-404.
20.
Simmons RK, Carlsen AH, Griffin SJ, Charles M, Christiansen JS, Borch-Johnsen K, Sandbaek
A, Lauritzen T: Variation in prescribing of lipid-lowering medication in primary care is associated
with incidence of cardiovascular disease and all-cause mortality in people with screen-detected
diabetes: findings from the ADDITION-Denmark trial. Diabetic medicine : a journal of the British Diabetic Association 2014, 31(12):1577-1585.
21.
Gudina EK, Amade ST, Tesfamichael FA, Ram R: Assessment of quality of care given to diabetic patients at Jimma University Specialized
Hospital diabetes follow-up clinic, Jimma, Ethiopia. BMC Endocrine Disorders 2011, 11(1):19.
22.
Sobngwi E, Ndour-Mbaye M, Boateng KA, Ramaiya KL, Njenga EW, Diop SN, Mbanya JC, Ohwovoriole
AE: Type 2 diabetes control and complications in specialised diabetes care centres of
six sub-Saharan African countries: the Diabcare Africa study. Diabetes Res Clin Pract 2012, 95(1):30-36.
23.
Uloko AE, Ofoegbu EN, Chinenye S, Fasanmade OA, Fasanmade AA, Ogbera AO, Ogbu OO,
Oli JM, Girei BA, Adamu A: Profile of Nigerians with diabetes mellitus - Diabcare Nigeria study group (2008):
Results of a multicenter study. Indian J Endocrinol Metab 2012, 16(4):558-564.
24.
Cameron A, Ewen M, Ross-Degnan D, Ball D, Laing R: Medicine prices, availability, and affordability in 36 developing and middle-income
countries: a secondary analysis. Lancet 2009, 373(9659):240-249.
25.
Ofori-Asenso R, Agyeman AA: Irrational Use of Medicines—A Summary of Key Concepts. Pharmacy 2016, 4, 35.
26.
Kayima J, Wanyenze RK, Katamba A, Leontsini E, Nuwaha F: Hypertension awareness, treatment and control in Africa: a systematic review. BMC cardiovascular disorders 2013, 13:54.
27.
Lloyd-Sherlock P, Beard J, Minicuci N, Ebrahim S, Chatterji S: Hypertension among older adults in low- and middle-income countries: prevalence, awareness
and control. International journal of epidemiology 2014, 43(1):116-128.
29.
Adeniyi OV, Yogeswaran P, Longo-Mbenza B, Ter Goon D: Uncontrolled Hypertension and Its Determinants in Patients with Concomitant Type 2
Diabetes Mellitus (T2DM) in Rural South Africa. PLoS One 2016, 11(3):e0150033.
30.
Hamid S, Groot W, Pavlova M: Trends in cardiovascular diseases and associated risks in sub-Saharan Africa: a review
of the evidence for Ghana, Nigeria, South Africa, Sudan and Tanzania. The aging male : the official journal of the International Society for the Study of
the Aging Male 2019:1-8.
31.
Rannanheimo PK, Tiittanen P, Hartikainen J, Helin-Salmivaara A, Huupponen R, Vahtera
J, Korhonen MJ: Impact of Statin Adherence on Cardiovascular Morbidity and All-Cause Mortality in
the Primary Prevention of Cardiovascular Disease: A Population-Based Cohort Study
in Finland. Value in health : the journal of the International Society for Pharmacoeconomics and
Outcomes Research 2015, 18(6):896-905.
32.
Rwegerera GM, Moshomo T, Gaenamong M, Oyewo TA, Gollakota S, Rivera YP, Masaka A,
Godman B, Shimwela M, Habte D: Health-related quality of life and associated factors among patients with diabetes
mellitus in Botswana. Alexandria Journal of Medicine 2018, 54(2):111-118.
33.
Barham AH, Goff DC, Jr., Chen H, Balasubramanyam A, Rosenberger E, Bonds DE, Bertoni
AG: Appropriateness of cholesterol management in primary care by sex and level of cardiovascular
risk. Preventive cardiology 2009, 12(2):95-101.
34.
James PA, Oparil S, Carter BL, Cushman WC, Dennison-Himmelfarb C, Handler J, Lackland
DT, LeFevre ML, MacKenzie TD, Ogedegbe O: 2014 evidence-based guideline for the management of high blood pressure in adults:
a report from the panel members appointed to the Eighth Joint National Committee (JNC
8). JAMA 2014, 311(5):507-520.
35.
White AD, Folsom AR, Chambless LE, Sharret AR, Yang K, Conwill D, Higgins M, Williams
OD, Tyroler HA: Community surveillance of coronary heart disease in the Atherosclerosis Risk in Communities
(ARIC) Study: methods and initial two years' experience. Journal of clinical epidemiology 1996, 49(2):223-233.
36.
Levey AS, Greene T, Schluchter MD, Cleary PA, Teschan PE, Lorenz RA, Molitch ME, Mitch
WE, Siebert C, Hall PM et al: Glomerular filtration rate measurements in clinical trials. Modification of Diet in
Renal Disease Study Group and the Diabetes Control and Complications Trial Research
Group. Journal of the American Society of Nephrology : JASN 1993, 4(5):1159-1171.
37.
Expert Panel on the Identification E, and Treatment of Overweight in Adults,: Clinical guidelines on the identification, evaluation, and treatment of overweight
and obesity in adults: executive summary. Expert Panel on the Identification, Evaluation,
and Treatment of Overweight in Adults. The American journal of clinical nutrition 1998, 68(4):899-917.
38.
World Health Organization (2011). Waist circumference and waist-hip ratio: report
of a WHO expert consultation, Geneva, 8-11 December 2008. Accessed on April 28, 2019,
from http://www.who.int/iris/handle/10665/44583.
39.
Law MR, Wald NJ, Rudnicka AR: Quantifying effect of statins on low density lipoprotein cholesterol, ischaemic heart
disease, and stroke: systematic review and meta-analysis. BMJ 2003, 326(7404):1423.
40.
Expert Panel on Detection E, Adults ToHBCi: Executive Summary of the Third Report of the National Cholesterol Education Program
(NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol
in Adults (Adult Treatment Panel III). JAMA 2001, 285(19):2486-2497.
41.
Chang KC, Soljak M, Lee JT, Woringer M, Johnston D, Khunti K, Majeed A, Millett C:
Coverage of a national cardiovascular risk assessment and management programme (NHS
Health Check): Retrospective database study. Preventive medicine 2015, 78:1-8.
42.
Ofori-Asenso R, Ilomaki J, Tacey M, Zomer E, Curtis AJ, Bell JS, Zoungas S, Liew D:
Patterns of statin use and long-term adherence and persistence among older adults
with diabetes. Journal of diabetes 2018, 10(9):699-707.
43.
Steen DL, Khan I, Becker L, Foody JM, Gorcyca K, Sanchez RJ, Giugliano RP: Patterns and predictors of lipid-lowering therapy in patients with atherosclerotic
cardiovascular disease and/or diabetes mellitus in 2014: Insights from a large US
managed-care population. Clinical cardiology 2017, 40(3):155-162.
44.
Lemstra M BD, Crawley A, Fung R.: Proportion and risk indicators of nonadherence to statin therapy: a meta-analysis. Can J Cardiol 2012, 28(5 ):574-580.
45.
Bai JW, Boulet G, Halpern EM, Lovblom LE, Eldelekli D, Keenan HA, Brent M, Paul N,
Bril V, Cherney DZI et al: Cardiovascular disease guideline adherence and self-reported statin use in longstanding
type 1 diabetes: results from the Canadian study of longevity in diabetes cohort. Cardiovascular diabetology 2016, 15:14-14.
46.
Sattar N, Preiss D, Murray HM, Welsh P, Buckley BM, de Craen AJ, Seshasai SR, McMurray
JJ, Freeman DJ, Jukema JW et al: Statins and risk of incident diabetes: a collaborative meta-analysis of randomised
statin trials. Lancet 2010, 375(9716):735-742.
47.
Godman B, Shrank W, Andersen M, Berg C, Bishop I, Burkhardt T, Garuoliene K, Herholz
H, Joppi R, Kalaba M et al: Policies to enhance prescribing efficiency in Europe: findings and future implications. Frontiers in pharmacology 2010, 1:141.
48.
Casagrande SS, Aviles-Santa L, Corsino L, Daviglus ML, Gallo LC, Espinoza Giacinto
RA, Llabre MM, Reina SA, Savage PJ, Schneiderman N et al: HEMOGLOBIN A1C, BLOOD PRESSURE, AND LDL-CHOLESTEROL CONTROL AMONG HISPANIC/LATINO
ADULTS WITH DIABETES: RESULTS FROM THE HISPANIC COMMUNITY HEALTH STUDY/STUDY OF LATINOS
(HCHS/SOL). Endocrine practice : official journal of the American College of Endocrinology and
the American Association of Clinical Endocrinologists 2017, 23(10):1232-1253.
49.
Tarn DM, Paterniti DA, Kravitz RL, Heritage J, Liu H, Kim S, Wenger NS: How much time does it take to prescribe a new medication? Patient education and counseling 2008, 72(2):311-319.
50.
Seliger SL, Weiss NS, Gillen DL, Kestenbaum B, Ball A, Sherrard DJ, Stehman-Breen
CO: HMG-CoA reductase inhibitors are associated with reduced mortality in ESRD patients. Kidney international 2002, 61(1):297-304.
51.
Tonelli M, Keech A, Shepherd J, Sacks F, Tonkin A, Packard C, Pfeffer M, Simes J,
Isles C, Furberg C et al: Effect of Pravastatin in People with Diabetes and Chronic Kidney Disease. Journal of the American Society of Nephrology 2005, 16(12):3748-3754.